Overcoming challenges in transitioning stem cell expansion from the laboratory to commercial production

Live30 webinars are thirty minute presentations designed to update you on the latest innovations, applications and data in a fast yet interactive format.

The stem cell field has advanced significantly over the past few decades, and most indications are that it will continue to do so at an ever-increasing pace. As more and more of these discoveries turn into potential therapies, scientists need to overcome challenges to transition these unique cells from laboratory conditions into commercial production. Traditional thinking around commercial production tends towards suspension culture, primarily based on the success of therapeutic protein manufacturing. However, stem cell therapies are significantly more complex. They require more sophisticated manufacturing platforms, and there is not always a one-size-fits all option. Many important considerations need to go into choosing the correct upstream manufacturing platforms including: biological compatibility, cost, time, labor, and analytics. This talk will cover some of these key considerations, as well as provide guidance for choosing the right platform to meet specific stem cell therapy production goals.

• Critical factors in choosing an approach to stem cell expansion, including biological compatibility, labor requirements, and analytics
• The relative advantages and disadvantages of adherent and suspension cell culture technologies for stem cell therapy production
• Discuss key considerations for choosing the right platform for stem cell therapy production

Ben Josey PhD

Field Application Scientist, Corning Life Sciences

Dr. Ben Josey is a Field Application Scientist at Corning Life Sciences. He received his Ph.D. in Pharmaceutical and Biomedical Sciences from the Medical University of South Carolina working on small molecule and biomaterial-based treatments for cancer and neurodegenerative disease. Dr. Josey has held several positions in academia focused on translational research to overcome immunological barriers facing cell therapies. Dr. Josey works extensively with research and process development groups optimizing assay and cell culture scale-up conditions for viral production and cellular therapeutics.

Watch now

SPEAKERS

Ben Josey PhD

Field Application Scientist, Corning Life Sciences

You might also like

From concept to clinic: overcoming the challenges of potency assays in cell and gene therapy development

Audrey Chang, Joe Newcome

10 December

in 10

Days

Register

Overcoming challenges in cell therapy production: rapid sterility testing

Seth Peterson

13 March

Watch

Industry highlights: switching from manual to automated hematopoietic stem cell (HSC) gene engineering

A Marques Gomes, A Rubio Gomes, U Bissels et al.

6 November

Watch

Analytical strategies for sterility and mycoplasma testing in biotherapies: from early development to production scale-up

Sharon Rouw, Michael Brewer

3 July

Watch

Analytical strategies for sterility and mycoplasma testing in biotherapies: from early development to production scale-up

Sharon Rouw, Michael Brewer

4 April

Watch